In addition, co-staining for the immune checkpoint molecule PD1 revealed a significantly reduced proportion of CD3+CD8+PD1+ T cells within the CD3+ T cell population (% of CD3+) in higher-grade tumors, which was true both for primary and recurrent meningiomas. Here, CD8A is linked to meningioma.